Antibody Firm KaloBios Prices $70M IPO in Lukewarm Debut
By Jennifer Boggs
Thursday, January 31, 2013
In the second biotech initial public offering (IPO) to price this week, antibody drug developer KaloBios Pharmaceuticals Inc. priced a slightly upsized offering of 8.75 million shares at $8 apiece for gross proceeds of $70 million. Like Stemline Therapeutics Inc., which priced an IPO Tuesday, KaloBios came in at the low end of its expected pricing range.
Sign up for Perspectives FREE e-mail newsletter.
Outside the U.S.: 1-404-262-5423
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Copyright @ 2013 AHC Media. Reproduction, reposting content is strictly prohibited.